Contineum Therapeutics (CTNM) Cash & Equivalents: 2023-2025
Historic Cash & Equivalents for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $42.6 million.
- Contineum Therapeutics' Cash & Equivalents rose 4.26% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 4.26%. This contributed to the annual value of $21.9 million for FY2024, which is 41.33% up from last year.
- According to the latest figures from Q3 2025, Contineum Therapeutics' Cash & Equivalents is $42.6 million, which was up 105.12% from $20.8 million recorded in Q2 2025.
- Contineum Therapeutics' Cash & Equivalents' 5-year high stood at $77.2 million during Q2 2024, with a 5-year trough of $15.5 million in Q4 2023.
- Over the past 3 years, Contineum Therapeutics' median Cash & Equivalents value was $22.2 million (recorded in 2024), while the average stood at $32.2 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 41.33% in 2024, then tumbled by 73.09% in 2025.
- Quarterly analysis of 3 years shows Contineum Therapeutics' Cash & Equivalents stood at $15.5 million in 2023, then surged by 41.33% to $21.9 million in 2024, then increased by 4.26% to $42.6 million in 2025.
- Its Cash & Equivalents was $42.6 million in Q3 2025, compared to $20.8 million in Q2 2025 and $22.5 million in Q1 2025.